Lipoprotein-Associated Phospholipase A
 2
 and C-Reactive Protein for Risk-Stratification of Patients With TIA

Cucchiara, Brett; Messé, Steve R.; Sansing, Lauren H; MacKenzie, Larami; Taylor, Robert; Pacelli, James; Shah, Qaisar; Kasner, Scott E.

doi:10.1161/strokeaha.109.553545

Cited by 69 publications

(66 citation statements)

References 22 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The link between elevated Lp-PLA2 activity and the risks of cardiovascular or cerebrovascular events has been investigated in several studies [25][26][27] . The present study with at least 90 days follow-up of 130 consecutive patients presented with acute IS showed that Lp-PLA2 mRNA expression of PBMNCs was significantly higher in patients with acute IS than in healthy controls.…”

Section: Discussionmentioning

confidence: 99%

Link between Lipoprotein-Associated Phospholipase A2 Gene Expression of Peripheral-Blood Mononuclear Cells and Prognostic Outcome after Acute Ischemic Stroke

Tsai

Chen

Lin

et al. 2012

JAT

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Link between Lipoprotein-Associated Phospholipase A2 Gene Expression of Peripheral-Blood Mononuclear Cells and Prognostic Outcome after Acute Ischemic Stroke

Tsai

Chen

Lin

et al. 2012

JAT

View full text Add to dashboard Cite

“…This distribution of hsCRP was almost identical with that of other stroke studies. 9,10 Characteristics of patients after stratification by relative risk of hsCRP are shown in Table 1. The patients with high hsCRP levels were significantly older, had higher body mass index and baseline National Institutes of Health Stroke Scale score, had histories of ischemic stroke and hypertension, had minor stroke, and received hypoglycemic treatment (Table 1).…”

Section: Patient Characteristicsmentioning

confidence: 99%

“…7 However, the association between hsCRP and recurrent stroke is less established. [8][9][10] On the contrary, disability from stroke has brought huge personal and societal burden. Though the predictive value of hsCRP in mortality has been proved, 11,12 its association with functional disability in the patients with stroke is still undefined.…”

mentioning

confidence: 99%

High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome

Li¹,

Wang²,

Meng³

et al. 2016

Stroke

View full text Add to dashboard Cite

A cute minor ischemic stroke and transient ischemic attack (TIA) are common, and patients with recent stroke or TIA are at high risk for subsequent stroke. It is estimated that 10% to 20% of these patients have a stroke within 3 months after the index event, most of which even occur within the first 2 days. [1][2][3][4] Though several clinical risk factors have been reported to be associated with recurrent stroke, these characteristics do not fully explain the risk of recurrence of stroke. 5 Inflammation is increasingly recognized as playing a central role in atherosclerosis and cardiovascular disease. 6 High-sensitive C-reactive protein (hsCRP), one of the most investigated inflammatory makers in cardiovascular research, has been independently associated with increased risk of recurrent cardiovascular events. 7 However, the association between hsCRP and recurrent stroke is less established. [8][9][10] On the contrary, disability from stroke has brought huge personal and societal burden. Though the predictive value of hsCRP in mortality has been proved, 11,12 its association with functional disability in the patients with stroke is still undefined. 13,14 The CHANCE (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) trial showed that the combination of clopidogrel and aspirin was superior to aspirin alone in reducing recurrent stroke in patients with acute minor stroke or high-risk TIA during 90-day and 1-year Background and Purpose-Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke. We aim to investigate the role of high-sensitive C-reactive protein (hsCRP) in predicting recurrent stroke and poor functional outcome. Methods-In the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial, 3044 (59%) consecutive patients from 73 (64%) prespecified centers had hsCRP levels measured. The primary outcome was any stroke within 90 days. The secondary outcome included combined vascular events and dependence or death defined as modified Rankin Scale score of 2 to 6 at 90 days and a new vascular event during 1-year follow-up. The associations of hsCRP with recurrent stroke and functional outcome were analyzed by using Cox proportional hazards and logistic regression models. Results-Elevated hsCRP (>3.0 mg/L) was observed in 32% of the study population. Patients with hsCRP >3 mg/L had an increased risk of recurrent stroke (adjusted hazard ratio, 1.46; 95% confidence interval, 1.08-1.98; P=0.039), ischemic stroke and combined vascular events, and poor functional outcome (adjusted odds ratio, 1.68; 95% confidence interval, 1.22-2.32; P=0.002) compared with those with hsCRP <1 mg/L within 90-day follow-up period. High hsCRP levels also independently predicted recurrent stroke during 1-year follow-up. There was no interaction of hsCRP levels with randomized antiplatelet therapy. Conclusions-High

show abstract

“…Candidate approaches have rendered few biomarkers to be useful in the prognosis of TIA patients such as C-reactive protein, 7 copeptin, 8 and lipoprotein-associated phospholipase A (Lp-PLA), 9 but the validity of the proposed biomarkers is debated. 10 Regarding biomarker discovery for etiology classification, only the activity of Lp-PLA2 has been shown effective for the detection of LAA, 9,11 and very recently pro-brain natriuretic peptide levels have been associated with the diagnosis of atrial fibrillation.…”

mentioning

confidence: 99%

Metabolomics predicts stroke recurrence after transient ischemic attack

et al. 2015

View full text Add to dashboard Cite

Objective: To discover, by using metabolomics, novel candidate biomarkers for stroke recurrence (SR) with a higher prediction power than present ones.Methods: Metabolomic analysis was performed by liquid chromatography coupled to mass spectrometry in plasma samples from an initial cohort of 131 TIA patients recruited ,24 hours after the onset of symptoms. Pattern analysis and metabolomic profiling, performed by multivariate statistics, disclosed specific SR and large-artery atherosclerosis (LAA) biomarkers. The use of these methods in an independent cohort (162 subjects) confirmed the results obtained in the first cohort.Results: Metabolomics analyses could predict SR using pattern recognition methods. Low concentrations of a specific lysophosphatidylcholine (LysoPC[16:0]) were significantly associated with SR. Moreover, LysoPC(20:4) also arose as a potential SR biomarker, increasing the prediction power of age, blood pressure, clinical features, duration of symptoms, and diabetes scale (ABCD2) and LAA. Individuals who present early (,3 months) recurrence have a specific metabolomic pattern, differing from non-SR and late SR subjects. Finally, a potential LAA biomarker, LysoPC(22:6), was also described. Conclusions:The use of metabolomics in SR biomarker research improves the predictive power of conventional predictors such as ABCD2 and LAA. Moreover, pattern recognition methods allow us to discriminate not only SR patients but also early and late SR cases. Neurology ® 2015;84:36-45 GLOSSARY ABCD2 5 age, blood pressure, clinical features, duration of symptoms, and diabetes scale; IDI 5 integrated discrimination improvement; LAA 5 large-artery atherosclerosis; Lp-PLA 5 lipoprotein-associated phospholipase A; NRI 5 net reclassification improvement; LysoPC 5 lysophosphatidylcholine; MS/MS 5 tandem mass spectrometry; PLS-DA 5 partial least squares discriminant analysis; ROC 5 receiver operating characteristic; SLC 5 solute carrier; SR 5 stroke recurrence.

show abstract

Lipoprotein-Associated Phospholipase A ₂ and C-Reactive Protein for Risk-Stratification of Patients With TIA

Cited by 69 publications

References 22 publications

Link between Lipoprotein-Associated Phospholipase A<sub>2</sub> Gene Expression of Peripheral-Blood Mononuclear Cells and Prognostic Outcome after Acute Ischemic Stroke

Link between Lipoprotein-Associated Phospholipase A<sub>2</sub> Gene Expression of Peripheral-Blood Mononuclear Cells and Prognostic Outcome after Acute Ischemic Stroke

High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome

Metabolomics predicts stroke recurrence after transient ischemic attack

Contact Info

Product

Resources

About

Lipoprotein-Associated Phospholipase A 2 and C-Reactive Protein for Risk-Stratification of Patients With TIA

Cited by 69 publications

References 22 publications

Link between Lipoprotein-Associated Phospholipase A<sub>2</sub> Gene Expression of Peripheral-Blood Mononuclear Cells and Prognostic Outcome after Acute Ischemic Stroke

Link between Lipoprotein-Associated Phospholipase A<sub>2</sub> Gene Expression of Peripheral-Blood Mononuclear Cells and Prognostic Outcome after Acute Ischemic Stroke

High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome

Metabolomics predicts stroke recurrence after transient ischemic attack

Contact Info

Product

Resources

About

Lipoprotein-Associated Phospholipase A ₂ and C-Reactive Protein for Risk-Stratification of Patients With TIA